If Trump indeed tanks your 401(k) to make himself and his friends even richer, the opposition party should make that the centerpiece of their attack heading into next year’s election.
pharmaceutical patents
Follow:
-
Martin Shkreli Is An Example Of Why We Need Publicly Funded Pharmaceutical Research
Facing national outrage, the 32-year-old CEO backed down from the 5000% price increase his company announced this week for the malaria and toxoplasmosis drug Daraprim, sparking an overdue debate about the outlandish cost of life-saving medicines.
-
Medical Injustice: Trans-Pacific Partnership Enriches Big Pharma at Cost Of People’s Health
Through "evergreening,” pharmaceutical companies could could retain ownership of and royalties to drugs for which their patents have expired – limiting access to generic forms of medicine that millions need.
-
Why Are We Letting Pharmaceutical Corporations Get Away With Robbery?
Drug and device makers paid doctors $380 million in speaking and consulting fees over a five-month period last year – and saw a healthy return on their investment.
